Safety and effectiveness of Ombitasvir/paritaprevir/ritonavir+dasabuvir in Hepatitis C Virus (HCV) with or without ribavirin infected patients in a real-life cohort from Latin America

Trial Profile

Safety and effectiveness of Ombitasvir/paritaprevir/ritonavir+dasabuvir in Hepatitis C Virus (HCV) with or without ribavirin infected patients in a real-life cohort from Latin America

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2018

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top